Investment Thesis
Cellectar Biosciences is a pre-revenue biotech company burning $4.8M annually with no commercialized products, representing high fundamental risk despite improving losses and adequate cash runway of ~1.7 years. While losses narrowed 51% YoY and the company maintains a strong cash position with minimal debt, the absence of revenue and negative operating cash flow underscore typical development-stage biotech financial distress. Success depends entirely on unproven clinical outcomes and pipeline advancement, not demonstrated business fundamentals.
Strengths
- Cash runway of approximately 1.7-2 years at current burn rate with $8.3M cash on hand
- Improving losses: net loss narrowed 51% YoY and EPS improved 80% YoY
- Minimal debt burden ($330.2K long-term debt) with favorable 0.10x debt-to-equity ratio
Risks
- Zero revenue generation with no clear commercialization timeline visible in financial statements
- Annual operating cash burn of $4.8M against minimal equity base of $3.3M creates dependency on successful capital raises
- Heavily negative returns (ROE -169.5%, ROA -50.8%) with no path to profitability evident from current fundamentals
- High cash burn relative to total assets (43% annual burn rate) and equity (145% annual burn rate)
Key Metrics to Watch
- Cash runway depletion rate and timing of next funding requirement
- Operating cash flow trend and path toward positive cash generation
- Revenue milestones from clinical trial progression and commercialization events
- Quarterly loss trajectory to validate continued improvement toward breakeven
Financial Metrics
Revenue
N/A
Net Income
-5.7M
EPS (Diluted)
$-1.33
Free Cash Flow
-4.8M
Total Assets
11.1M
Cash
8.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-169.5%
ROA
-50.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.90x
Quick Ratio
1.90x
Debt/Equity
0.10x
Debt/Assets
57.6%
Interest Coverage
N/A
Long-term Debt
330.2K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:00:21.862815 |
Data as of: 2026-03-31 |
Powered by Claude AI